NCT05171946View on ClinicalTrials.gov

Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 20, 2022

Primary Completion Date

March 1, 2023

Study Completion Date

July 1, 2023

Conditions
SafetyVaccine ReactionVaccine Adverse ReactionImmunization; Infection
Interventions
DRUG

S.opt.FL COVID-19 pDNA vaccine

Low-Dose: (1mg) level

DRUG

S.opt.FL COVID-19 pDNA vaccine

Mid-Dose: (2mg) level

DRUG

S.opt.FL COVID-19 pDNA vaccine

High-Dose: (4mg) level

Sponsors

Collaborators (1)

ICON plc
All Listed Sponsors
collaborator

ICON plc

INDUSTRY

lead

Iman Almansour

OTHER

NCT05171946 - Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults | Biotech Hunter | Biotech Hunter